ISATUXIMAB PLUS POMALIDOMIDE-DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS BY PRIOR ANTI-CD38 EXPOSURE FROM THE PHASE 3 IRAKLIA TRIAL

EHA Library, Albert Oriol, 4207779

BONE MARROW QUALITY INDEX (BMQI) AS A MARKER OF SAMPLE QUALITY IN POST-TREATMENT MRD ASSESSMENT: DATA FROM THE REMNANT TRIAL

EHA Library, Jón Þórir Óskarsson, 4207783

COMPARATIVE EFFICACY AND SAFETY OF CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY VERSUS BISPECIFIC ANTIBODIES FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

EHA Library, Rahul Falodia, 4207786

OUTCOMES AND UNMET NEED IN LENALIDOMIDE-EXPOSED AND LENALIDOMIDE-REFRACTORY 2-4L RRMM FLATIRON PATIENTS

EHA Library, Omar Alkharabsheh, 4207788

MORTALITY AND CLINICAL RISK FACTORS IN PATIENTS WITH MULTIPLE MYELOMA.

EHA Library, Maria Ordoñez Garcia, 4207790

REAL-WORLD PATIENT CHARACTERISTICS, GENERAL SAFETY PROFILE, AND TREATMENT PATTERNS OF ELRANATAMAB (ELRA) USE IN RELAPSED REFRACTORY MULTIPLE MYELOMA: INTERIM RESULTS OF THE AMBRELA STUDY

EHA Library, Thomas Chalopin, 4207792

OVERALL SURVIVAL AND TIME TO NEXT TREATMENT IN GERMAN POST-LEN RRMM PATIENTS: A REAL-WORLD PERSPECTIVE

EHA Library, Florian Weissinger, 4207795

THE RELATIONSHIP BETWEEN MINIMUM RESIDUAL DISEASE NEGATIVE COMPLETE RESPONSE RATE AND PROGRESSION-FREE SURVIVAL TREATMENT EFFECTS IN RELAPSED REFRACTORY MULTIPLE MYELOMA: A NOVEL PERSPECTIVE

EHA Library, C. Ola Landgren, 4207796

PATIENT PREFERENCES FOR ATTRIBUTES OF RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATMENT: FINDINGS FROM A DISCRETE CHOICE EXPERIMENT

EHA Library, Thomas W LeBlanc, 4207797

CERTIFIED MEDICAL EDUCATION LEADS TO CLAIMS CONFIRMED CHANGES IN CLINICAL PRACTICE REGARDING MANAGEMENT OF MULTIPLE MYELOMA

EHA Library, Sarah Elizabeth Bomba, 4207798

MIF/MTOR PATHWAY DRIVES INFLAMMATION IN IMCD WITH ANA POSITIVITY PRONE TO SEVERE DISEASE AND WORSE PROGNOSIS

EHA Library, Shengnan Ding, 4207800

IMPACT OF BRIDGING THERAPY AND DISEASE RESPONSE ON OUTCOMES AFTER ARI0002H BCMA CAR-T IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Anna de Daniel, 4207802

FIRST-LINE DARATUMUMAB–LENALIDOMIDE–DEXAMETHASONE IN NEWLY DIAGNOSED SYSTEMIC AL AMYLOIDOSIS: A UK NATIONAL AMYLOIDOSIS CENTRE EXPERIENCE

EHA Library, Suraj Vasudevan, 4207803

PROGNOSTIC ROLE OF PROGRESSION IN WALDENSTRÖM MACROGLOBULINEMIA PATIENTS, A REPORT FROM THE FRENCH INNOVATIVE LYMPHOMA ORGANIZATION (FILO) REGISTRY

EHA Library, Lydia Montes, 4207805

PATIENT-REPORTED OUTCOMES (PROS) AND MINIMAL RESIDUAL DISEASE (MRD) NEGATIVITY IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS TREATED WITH QUADRUPLET THERAPY: POST-HOC ANALYSIS OF GMMG-HD7 TRIAL

EHA Library, Elias K. Mai, 4207806

IMPACT OF SPECIFIC CYTOGENETIC ABNORMALITIES ON MRD KINETICS AND PROGNOSTIC VALUE IN MULTIPLE MYELOMA

EHA Library, Alberto Blanco Sánchez, 4207808

IGH REARRANGEMENTS IN AL AMYLOIDOSIS, CLINICAL CHARACTERISTICS AND OUTCOMES OF A POPULATION BASED STUDY

EHA Library, Flores Weverling, 4207809

THE INTERVAL AND RISK FACTORS FROM LOSS OF COMPLETE RESPONSE TO DEFINITE RELAPSE IN NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION

EHA Library, Yang Liu, 4207810

INFLAMMATION SCORE (I-SCORE) IN ELDERLY PATIENTS WITH MULTIPLE MYELOMA: A NEW EASY TOOL TO ASSESS PROGNOSIS.

EHA Library, Velia Bongarzoni, 4207811

ROLE OF COMPLETE OR VERY GOOD PARTIAL RESPONSE (CR/VGPR) AND EARLY PROGRESSION AFTER DEXAMETHASONE RITUXIMAB CYCLOPHOSPHAMIDE (DRC) +/- BORTEZOMIB IN WALDENSTRÖM MACROGLOBULINEMIA IN THE ECWM1 TRIAL

EHA Library, Pierre Morel, 4207812

UPDATED SAFETY OF ISATUXIMAB SUBCUTANEOUS AT-HOME ADMINISTRATION BY ON-BODY INJECTOR IN RELAPSED/REFRACTORY MULTIPLE MYELOMA IN THE PHASE 3 IRAKLIA STUDY

EHA Library, Claudio Cerchione, 4207813

PROGNOSTIC VALUE OF SERUM FERRITIN KINETICS IN ANTI-BCMA CAR-T THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, James Di Palma-Grisi, 4207815

MOLECULAR MARKERS AS A POSSIBLE FACTOR IN PROGRESSION IN MULTIPLE MYELOMA

EHA Library, Zhanna Kozich, 4207817

PROGNOSTIC VALUE OF TIME-TO-TREATMENT AND REGIMENS IN WALDENSTRÖM MACROGLOBULINEMIA: A REAL-WORLD MULTICENTER STUDY

EHA Library, Kyungju Kim, 4207819

REAL-WORLD EFFECTIVENESS AND SAFETY OF DARATUMUMAB, POMALIDOMIDE AND DEXAMETHASONE (DPD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: PRELIMINARY RESULTS OF THE MULTICENTER EMN DARAPD STUDY

EHA Library, Ombretta Annibali, 4207828

THE HIDDEN COST OF INFECTION, SEPTIC SHOCK AND SURVIVAL IN WALDENSTRÖM MACROGLOBULINEMIA

EHA Library, Abdulhaq Al Jafari, 4207830

INCIDENCE AND SURVIVAL OF PLASMA CELL LEUKAEMIA IN THE MODERN ERA: AN ENGLISH COHORT STUDY FROM THE UNCOVER GROUP AND UKMRA FRAILTY GROUP.

EHA Library, Thea Chandler, 4207831

CLINICAL FACTORS AT FIRST MOBILIZATION FOR ASSESSING THE NEED TO STORE EXCESS CRYOPRESERVED AUTOLOGOUS STEM CELLS FOR FUTURE SALVAGE TRANSPLANTATION IN MULTIPLE MYELOMA

EHA Library, Laura Renners, 4207834

FACTORS INFLUENCING LONG PROGRESSION-FREE SURVIVAL IN MULTIPLE MYELOMA PATIENTS RECEIVING IXAZOMIB-BASED ALL-ORAL REGIMENS

EHA Library, Yanjuan He, 4207836

LOWER INFECTIONS WITH ELRANATAMAB (ELRA) IN MULTIPLE MYELOMA (RRMM) IN REAL-WORLD SETTINGS THAN IN MAGNETISMM-3 (MM-3)

EHA Library, Rahul Banerjee, 4207837

MUTANT SHP2 CONDENSATES PROMOTE GENOMIC INSTABILITY THROUGH PAK1-ASSOCIATED MICROTUBULE DYSREGULATION IN JMML

EHA Library, Yun Chen, 4207842

GALECTIN-1 AS A MEDIATOR OF THROMBOTIC RISK IN MYELOPROLIFERATIVE NEOPLASMS?

EHA Library, Natalie J Jooss, 4207843

COMBINED MEK AND PI3KΔ INHIBITION OVERCOMES RASA2-MEDIATED RESISTANCE IN PTPN11-MUTANT JMML

EHA Library, Yuming Zhao, 4207844

PRECLINICAL EVALUATION OF INCA035784, A NOVEL T-CELL–REDIRECTING ANTIBODY FOR THE TREATMENT OF MUTCALR-DRIVEN MYELOPROLIFERATIVE NEOPLASMS (MPNS)

EHA Library, Eleanor Murphy, 4207846

BLOOD-BASED SINGLE-CELL PROFILING OF CIRCULATING PROGENITORS RESOLVES DISEASE STATE, PROGRESSION RISK, AND CLONAL IDENTITY ACROSS MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Gal Dadi, 4207848

MICE EXPRESSING KITD814V IN THE MAST CELL LINEAGE SHOW A SYSTEMIC MASTOCYTOSIS PHENOTYPE WITH SKIN LESIONS THAT CAN BE REVERSED BY TREATMENT WITH SPECIFIC TYROSINE KINASE INHIBITORS

EHA Library, Simona Stivala, 4207850

JAK2V617F SIGNALLING DRIVES A PATHOLOGICAL PHOSPHORYLATION PROFILE ON HYPOXIA INDUCIBLE FACTOR-1 THAT ALTERS FUNCTION IN HSCS

EHA Library, Ruth Ellerington, 4207852

SHARED GENETIC ARCHITECTURE OF CLONAL HAEMATOPOIESIS AND LEUKOCYTE TELOMERE LENGTH IMPLICATES VSIG4 ON THE X CHROMOSOME AS A NOVEL RISK LOCUS FOR TET2-MUTANT CLONAL HAEMATOPOIESIS

EHA Library, Aleksandra Kamizela, 4207853

JAK2V617F-POSITIVE MPN MICROENVIRONMENT DRIVES T LYMPHOCYTE EXHAUSTION

EHA Library, Lorena Pontes, 4207854

AN INDUCIBLE TRANSGENIC SCL-CRE;KITD814V MOUSE MODEL RECAPITULATES ADVANCED SYSTEMIC MASTOCYTOSIS WITH SM-AHN AND VALIDATES AVAPRITINIB RESPONSE

EHA Library, Martina Konantz, 4207857

INVESTIGATING GSK3Β SIGNALLING AXIS AS A NOVEL THERAPEUTIC VULNERABILITY IN JAK2V617F MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Aparna Sinha, 4207858

INCB160058 SELECTIVELY TARGETS JAK2V617F-DRIVEN HEMATOPOIESIS IN DIVERSE AND DRUG-RESISTANT MODELS OF MYELOPROLIFERATIVE NEOPLASMS (MPNS)

EHA Library, Hamza Celik, 4207860

DISTINCT CYTOKINE EXPRESSION SIGNATURES IN ADOLESCENT AND YOUNG ADULTS (AYA) AND NON-AYA PATIENTS WITH BCR::ABL NEGATIVE MYELOPROLIFERATIVE NEOPLASM (MPN)

EHA Library, Alice Diepers, 4207864

USP22 STABILIZES NAP1L1 TO ACTIVATE PI3K/AKT SIGNALING AND PROMOTE CLONAL EXPANSION OF CD34⁺ CELLS IN MYELODYSPLASTIC SYNDROMES

EHA Library, Lijuan Li, 4207867

HDAC INHIBITORS SUPPRESS SURVIVAL OF NEOPLASTIC MAST CELLS AND COUNTERACT CYTOKINE-INDUCED UPREGULATION OF IMMUNE CHECKPOINT MOLECULES PD-L1, CD47 AND TIM-3

EHA Library, Yüksel Filik Schüppler, 4207869

ANAGRELIDE INDUCED GRP78 PRODUCTION IN MPN CELLS LEADING TO LYSYL OXIDASE EXPRESSION IN BONE MARROW STROMAL CELLS

EHA Library, YUMA SAKAMOTO, 4207871

DIVESIRAN, A NOVEL GALNAC CONJUGATED SIRNA, REDUCES PHLEBOTOMIES, IMPROVES IRON STORES AND SYMPTOMS IN POLYCYTHEMIA VERA PATIENTS IN SANRECO PHASE 1 STUDY.

EHA Library, Marina Kremyanskaya, 4207874

A NOVEL MACHINE LEARNING-BASED APPROACH IN 1206 PATIENTS RELIABLY DIFFERENTIATES CLONAL FROM NON-CLONAL EOSINOPHILIA: THE EOSINOPHILIA DIFFERENTIATION SCORE (EDS)

EHA Library, Johannes Lübke, 4207875

NOVEL PROGNOSTIC RISK SCORING SYSTEM FOR PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED WITH MIDOSTAURIN OR AVAPRITINIB: DEVELOPMENT AND VALIDATION OF THE REVISED MUTATION-ADJUSTED RISK SCORE

EHA Library, Johannes Lübke, 4207876

TREATMENT STRATEGIES AND LIVE BIRTH RATES IN MPN PREGNANCIES: A SINGLE-CENTER ANALYSIS OF 165 PREGNANCIES

EHA Library, Kristine Poghosyan, 4207877

THROMBOEMBOLIC AND PROGRESSION EVENTS IN PHLEBOTOMY-DEPENDENT PATIENTS WITH POLYCYTHEMIA VERA (PV): LONG-TERM RESULTS FROM THE PHASE 2 REVIVE AND THRIVE OPEN-LABEL EXTENSION RUSFERTIDE STUDIES

EHA Library, Naveen Pemmaraju, 4207878

BENEFIT OF RUSFERTIDE MAINTAINED IN PATIENTS (PTS) WITH LOW-RISK OR HIGH-RISK POLYCYTHEMIA VERA (PV): EFFICACY AND SAFETY SUBGROUP ANALYSIS FROM THE RANDOMIZED CONTROLLED PHASE 3 VERIFY STUDY

EHA Library, Valentin Garcia Gutierrez, 4207880

LONG-TERM OUTCOMES WITH SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVITY IN BELANTAMAB MAFODOTIN–TREATED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: AN UPDATE FROM DREAMM-8

EHA Library, Meletios Dimopoulos, 4207780

ELIGIBILITY AND TREATMENT DECISION FACTORS, ALTERNATIVE TREATMENTS AND OUTCOMES OF MULTIPLE MYELOMA PATIENTS CONSIDERED FOR CAR T-CELL THERAPY IN GERMANY. A REAL-WORLD TRINETX DATABASE STUDY.

EHA Library, Zuzana Dostalova, 4207781

PLASMACYTOMA REDUCED QUICKLY IN PATIENTS(PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA BY APONERMIN +KT-DECP REGIMEN

EHA Library, Aijun Liu, 4207782

CAR-T VERSUS BCMA BISPECIFIC ANTIBODIES AFTER PRIOR BCMA THERAPY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MULTICENTER REAL-WORLD ANALYSIS

EHA Library, Shebli Atrash, 4207784

CIBMTR REAL-WORLD OUTCOMES OF OLDER PATIENTS TREATED WITH IDECABTAGENE VICLEUCEL

EHA Library, Doris Hansen, 4207785

EFFICACY OF SEQUENCED BCMA-DIRECTED THERAPIES IN RELAPSED/REFRACTORY MULTIPLE MYELOMA – A RETROSPECTIVE, MULTICENTER, INTERNATIONAL COHORT STUDY (SEQ-BCMA STUDY)

EHA Library, Christoph Schaefers, 4207787

SIGNIFICANT IMPROVEMENTS IN SURVIVAL OUTCOMES IN SMOLDERING MULTIPLE MYELOMA: A POPULATION-BASED STUDY

EHA Library, Malin Hultcrantz, 4207789

DEEP PERIPHERAL IMMUNE PHENOTYPING REVEALS PROFOUND T-CELL SENESCENCE, NK-CELL DYSREGULATION, AND MONOCYTE SKEWING IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Yajing Zhang, 4207791

RISK FACTORS FOR VENOUS THROMBOEMBOLISM IN 8,672 MYELOMA PATIENTS FROM THE SWEDISH MYELOMA REGISTRY

EHA Library, Mariana Villegas- Scivetti, 4207793

THE ROLE OF WHOLE-BODY STIR MRI IN ASSESSING FIRST BIOCHEMICAL RELAPSE IN MULTIPLE MYELOMA AND INFORMING THE INITIATION OF SECOND-LINE THERAPY

EHA Library, Tania Kreuzbauer, 4207794

REAL‑WORLD OUTCOMES OF TECLISTAMAB IN HEAVILY PRETREATED RELAPSED/REFRACTORY MULTIPLE MYELOMA WITH TRUE EXTRAMEDULLARY DISEASE: RESULTS FROM THE DANISH ABCD STUDY

EHA Library, Astrid Hundebøll Torpe, 4207799

SUSTAINED MRD NEGATIVITY FOR 4 YEARS IS A SIGNIFICANT MARKER OF PROGNOSIS IN PATIENTS WITH HIGH-RISK MULTIPLE MYELOMA

EHA Library, Juan Li, 4207801

COMPLETE CARDIAC RESPONSE IMPROVES THE SURVIVAL OF PATIENTS WITH AL AMYLOIDOSIS AND IMPAIRED GLOBAL LONGITUDINAL STRAIN

EHA Library, Foteini Theodorakakou, 4207804

INFLAMMATORY MIMICS: MASS SPECTROMETRY RESOLVES FALSE-POSITIVE PARAPROTEINS ON SERUM IMMUNOFIXATION

EHA Library, Neela Easton, 4207807

CLONAL PLASMA CELL S-PHASE AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION PREDICTS SURVIVAL OUTCOMES IN MULTIPLE MYELOMA

EHA Library, Maximilian Steinhardt, 4207814

BCMA CAR-T THERAPY WITH RADIOTHERAPY BRIDGING AND MAINTENANCE ACHIEVES UNPRECEDENTED DURABLE RESPONSE IN EXTRAMEDULLARY MYELOMA

EHA Library, lili Zhou, 4207816

COMPARATIVE EFFICACY OF LINVOSELTAMAB VERSUS TECLISTAMAB IN TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED MATCHING-ADJUSTED INDIRECT COMPARISON WITH LONGER FOLLOW-UP

EHA Library, Hans C. Lee, 4207818

MATCHING-ADJUSTED INDIRECT COMPARISON FOR BELANTAMAB MAFODOTIN WITH POMALIDOMIDE AND DEXAMETHASONE VS DARATUMUMAB WITH POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Meral Beksaç, 4207820

COMPARISON OF CLONOTYPIC PEPTIDE (EASYM) AND INTACT IMMUNOGLOBULIN LIGHT CHAIN (EXENT) PERIPHERAL BLOOD-BASED MASS SPECTROMETRY IN MULTIPLE MYELOMA

EHA Library, Jessie Zhao, 4207821

FRAILTY AND QUALITY OF LIFE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS

EHA Library, Klara Frederikke Koue Rydahl, 4207822

ANTIDIABETIC MEDICATION USE AND MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE: ASSOCIATIONS WITH PREVALENCE AND M-PROTEIN TRAJECTORIES IN THE ISTOPMM STUDY

EHA Library, Kirstine Ostenfeld Larsen, 4207823

UNRESTRAINED LYMPHOCYTOSIS AS A PREDICTOR OF A DELAYED NON-ICANS NEUROTOXICITY FOLLOWING CILTACABTAGENE AUTOLEUCEL CAR T-CELL THERAPY IN MULTIPLE MYELOMA: A REAL-WORLD SINGLE-CENTER EXPERIENCE

EHA Library, Inna Shaforostova, 4207824

OUTCOMES AFTER FRONTLINE QUADRUPLET FAILURE IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Luis Gerardo Rodriguez-Lobato, 4207825

COMPREHENSIVE MGUS IDENTIFICATION OVER 13 YEARS ALLOWS REAL WORLD ANALYSIS OF FOLLOW UP AND OUTCOMES

EHA Library, Aidan Haslam, 4207826

REAL-WORLD OUTCOMES AND SUBSEQUENT TREATMENT UTILIZATION FOLLOWING ANTI-B-CELL MATURATION ANTIGEN ANTIBODY-DRUG CONJUGATE EXPOSURE IN PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Meletios Dimopoulos, 4207827

MINIMAL RESIDUAL DISEASE TRAJECTORIES IN NEWLY DIAGNOSED MULTIPLE MYELOMA AND SURVIVAL OUTCOMES; A RETROSPECTIVE COHORT STUDY

EHA Library, Panagiotis Malandrakis, 4207829

NORMAL PLASMA CELLS AS A PROGNOSTIC BIOMARKER AND PREDICTOR OF EARLY SEVERE INFECTION IN NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Qun Li, 4207832

MULTI-OMICS PROFILING AND MEASURABLE RESIDUAL DISEASE ANALYSIS USING LIQUID BIOPSIES FROM MULTIPLE MYELOMA PATIENTS IN CLINICAL ROUTINE – A TRANSLATIONAL STUDY

EHA Library, Jan Vorwerk, 4207835

FIRST-LINE USE OF CARFILZOMIB-BASED REGIMENS IMPROVES SURVIVAL OF NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH EXTRAMEDULLARY PLASMACYTOMAS: A REAL-WORLD RETROSPECTIVE STUDY

EHA Library, Zheng Ge, 4207838

EFFICACY AND SAFETY OF CESNICABTAGENE AUTOLEUCEL (ARI0002H), AN ACADEMIC BCMA‑TARGETED CAR T‑CELL THERAPY, IN RELAPSED/REFRACTORY LIGHT‑CHAIN AMYLOIDOSIS

EHA Library, Jose Miguel Mateos Perez, 4207839

SAFETY AND EFFICACY OF AUTOLOGOUS DUAL TARGETING BCMA/CD19 CAR-T FKC289 IN SUBJECTS WITH RELAPSED / REFRACTORY LIGHT CHAIN AMYLOIDOSIS

EHA Library, Jing Li, 4207840

PRECLINICAL CHARACTERIZATION OF CGT1145, A NOVEL, WILD-TYPE-SPARING, JAK2 V617F MUTANT-SELECTIVE INHIBITOR

EHA Library, Mark J Chicarelli, 4207841

SIMULTANEOUS ANTIBODY TARGETING OF MUTANT CALRETICULIN TO PROXIMAL AND DISTAL EPITOPES FOR ENHANCED PRECISION MEDICINE FOR TYPE 1 VS TYPE 2 MYELOFIBROSIS

EHA Library, Denis Tvorogov, 4207845

A HUMANIZED OSSICLE MODEL OF MYELOFIBROSIS REVEALS THPO-DRIVEN FIBROSIS, OSTEOSCLEROSIS AND SPP1-DEPENDENT MICROENVIRONMENTAL REMODELING

EHA Library, Stefan Scheding, 4207847

LNK/SH2B3 VARIANTS AT THE N-TERMINAL AND PH DOMAIN DEFINE A NOVEL MODULATORY REGION FOR JAK2-MEDIATED BIOLOGICAL ACTIVITY IN MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Laura Eugenia Velazquez Medina, 4207849

PRECLINICAL EVIDENCE OF TARGETING ACVR1/HEPCIDIN BY NUVISERTIB, AN ORAL INVESTIGATIONAL PIM1 KINASE INHIBITOR, SUGGESTS POTENTIAL MECHANISTIC BASIS FOR HEMOGLOBIN BENEFIT IN MYELOFIBROSIS

EHA Library, Joseph M Scandura, 4207855

FROM CLONAL HEMATOPOIESIS TO MYELOPROLIFERATIVE NEOPLASMS: A THROMBOINFLAMMATORY PERSPECTIVE ON JAK2V617F

EHA Library, Lea Löffler, 4207856

LOSS OF CBP DRIVES MYELOID-DERIVED SUPPRESSOR CELL EXPANSION AND PREDICTS POOR PROGNOSIS VIA METTL14-DEPENDENT M6A MODIFICATION IN MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Jian Huang, 4207859

DISCOVERY AND CHARACTERIZATION OF DMR-001, AN FC-NULL, HALF-LIFE OPTIMIZED MONOCLONAL ANTIBODY SELECTIVELY TARGETING MUTANT CALRETICULIN

EHA Library, Shannon E. Elf, 4207861

SINGLE-CELL TRANSCRIPTOMICS REVEALS SHARED DISEASE-SPECIFIC HEMATOPOIETIC STEM CELL PROGRAMS IN JMML AND RALD AND JMML-SPECIFIC ZEB1 HYPERACTIVATION

EHA Library, Alexandr Ikonnikov, 4207862

MEGACALR IHC: AI-DRIVEN QUANTIFICATION OF MUTANT CALR EXPRESSION IN MEGAKARYOCYTES

EHA Library, Thomas Fletcher, 4207863

JAK2 VAF IN POLYCYTHEMIA VERA PATIENTS TREATED WITH ROPEGINTERFERON AND RUXOLITINIB IN A REAL LIFE COHORT: RESULTS FROM A SINGLE CENTER RETROSPECTIVE STUDY.

EHA Library, Valentina Giai, 4207865

DNA METHYLATION PROFILING IDENTIFIES MYC AND MAPK PATHWAY DEREGULATION IN TRIPLE NEGATIVE MDS/MPN WITH SF3B1 MUTATION AND THROMBOCYTOSIS

EHA Library, Julien Broseus, 4207866

DECIPHERING THE IMPACT OF CBL DOUBLE-HIT ALTERATIONS ACROSS MYELOID MALIGNANCIES

EHA Library, Anna Stengel, 4207868

MUTANT CALRETICULIN-SPECIFIC MONOCLONAL ANTIBODY, INCA033989, PRODUCES CLONAL MOLECULAR RESPONSES THAT CORRELATE WITH CLINICAL RESPONSES IN PATIENTS WITH MYELOFIBROSIS

EHA Library, Jyoti Nangalia, 4207872

THE EFFECT OF BEZUCLASTINIB ON THE PATHOBIOLOGY OF ADVANCED SYSTEMIC MASTOCYTOSIS: RESULTS FROM THE PIVOTAL APEX TRIAL

EHA Library, Tracy I. George, 4207873

EFFECT OF RUSFERTIDE ON CYTOREDUCTIVE THERAPY USE IN PATIENTS WITH PHLEBOTOMY DEPENDENT POLYCYTHEMIA VERA: POST HOC ANALYSIS FROM THE RANDOMIZED CONTROLLED PHASE 3 VERIFY STUDY

EHA Library, Francesca Palandri, 4207879

LONG-TERM EFFICACY OF GECACITINIB ON MYELOFIBROSIS GRADE AND GENE MUTATION LEVEL: A PHASE IIIB EXTENSION STUDY IN PREVIOUSLY ENROLLED PATIENTS

EHA Library, Yi Zhang, 4207881